File S1. Supporting Information File

Efficacy of Short-Term High-Dose Statin Pretreatment in Prevention of Contrast-Induced Acute Kidney Injury : Updated Study-Level Meta-Analysis of 13 Randomized Controlled Trials

Joo Myung Lee, MD, MPH^{1†}, Jonghanne Park, MD^{1†}, Ki-Hyun Jeon, MD¹,

Ji-hyun Jung, MD¹, Sang Eun Lee, MD, PhD¹, Jung-Kyu Han, MD, PhD¹, <u>Hack-Lyoung Kim, MD, PhD²</u>, Han-Mo Yang, MD, PhD¹, Kyung

Woo Park, MD, PhD¹, Hyun-Jae Kang, MD, PhD¹, Bon-Kwon Koo, MD, PhD¹, Sang-Ho Jo, MD³,

Hyo-Soo Kim, MD, PhD^{1,4}

¹Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea

²Cardiovascular Center, Seoul National University Boramae Medical Center, Seoul, Korea

³Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea

⁴Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.

Supporting Methods

Method S1. Search strategy

	Pubmed			EMBASE			Cochrane Library	
#21	#18 AND #19 AND #20	128	#22	#21 AND ('clinical trial'/de OR 'controlled clinical trial'/de OR 'randomized controlled trial'/de)	299	#21	#18 AND #19 AND #20	38
#20	#12 OR #13 OR #14 OR #15 OR #16 OR #17	483,79 0	#21	#18 AND #19 AND #20	1,133	#20	#12 OR #13 OR #14 OR # 15 OR #16 OR #17	11,822
#19	#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11	38,965	#20	#12 OR #13 OR #14 OR #1 5 OR #16 OR #17	715,000	#19	#3 OR #4 OR #5 OR #6 O R #7 OR #8 OR #9 OR #1 0 OR #11	7,380
#18	#1 OR #2	789,75 6	#19	#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11	110,188	#18	#1 OR #2	22,825
#17	'kidney failure'	79,639	#18	#1 OR #2	1,376,05 6	#17	'kidney failure' :ti,ab,kw	5,096
#16	'renal insufficiency'	31,322	#17	'kidney failure'/syn	253,346	#16	'renal insufficiency':ti,ab,kw	1,504
#15 #14 #13	'renal failure' 'kidney injury' 'nephrotoxicity'	75,804 35,238 12,899	#16 #15 #14	'renal insufficiency' /syn 'renal failure' /syn 'kidney injury' /syn	253,346 253,346 39,568	#15 #14 #13	'renal failure' :ti,ab,kw 'kidney injury' :ti,ab,kw 'nephrotoxicity' :ti,ab,kw	3,015 866 1,221
#12	'nephropathy'	447,93 5	#13	'nephrotoxicity'/syn	55,283	#12	'nephropathy':ti,ab,kw	3,281
#11 #10 #9 #8	'cerivastatin' 'lovastatin' 'pravastatin' 'simvastatin'	698 9,558 4,078 7,670	#12 #11 #10 #9	' nephropathy' /syn ' cerivastatin' /syn ' lovastatin' /syn ' pravastatin' /syn	692,175 4,015 13,385 16,960	#11 #10 #9 #8	' cerivastatin' :ti,ab,kw ' lovastatin' :ti,ab,kw 'pravastatin' :ti,ab,kw 'simvastatin' :ti,ab,kw	145 760 1,335 2,000

#7 #6 #5 #4 #3	'rosuvastatin' 'atorvastatin' 'hydroxymethylglutaryl' 'hmg-coa' 'statin'	2,100 6,201 23,081 9,392 31,933	#8 #7 #6 #5 #4	'simvastatin'/syn 'rosuvastatin'/syn 'atorvastatin'/syn 'hydroxymethylglutaryl' 'hmgcoa'/syn	27,935 8,250 24,302 101,523 102,934	#7 #6 #5 #4 #3	'rosuvastatin' :ti,ab,kw 'atorvastatin' :ti,ab,kw 'hydroxymethylglutaryl' 'hmg-coa' :ti,ab,kw 'statin' :ti,ab,kw	724 2,383 3279 683 2,114
#2	radiocontrast	913 789,46	#3	'statin'/syn	21,670	#2	radiocontrast	116
#1	'contrast'	3	#2	radiocontrast	1,175	#1	'contrast' :ti,ab,kw	22,804
			#1	'contrast' /syn	1,375,90 1			

Method S2. Characteristics of the Excluded Studies

No.	Title	First Author	Journal	Main Reason for Exclusion
1	Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions	Khanal, S et al.	Am J Med 2005	Not a randomized controlled trial
2	Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention	Patti, G et al.	Am J Cardiol 2008	Not a randomized controlled trial
3	Association between high sensitivity C- reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin	Su, J. Z et al.	Zhonghua Xin Xue Guan Bing Za Zhi 2011	Observational study Multiple treatment group according to statin dose
4	Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users	de Oliveira, M. S. et al.	Revista Brasileira de Cardiologia Invasiva 2012	All the study population pre-defined to be on chronic statin use
5	Effect of statins in contrast-induced nephropathy after coronary angiography	Selmi, W et al.	JACC: Cardiovascular Interventions 2013	Post-hoc analysis of previeous RCT
6	The potential role of statins in contrast nephropathy	Attallah, N et al	Clin Nephrol 2004	Not a randomized controlled trial
7	Statin therapy and contrast-induced nephropathy after primary angioplasty	Bouzas-Mosquera, A et al.	Int J Cardiol 2009	Not a randomized controlled trial

8	Preventive effect of statin pretreatment on contrast-induced acute kidney injury in patients undergoing coronary angioplasty: Propensity score analysis from a multicenter registry	Hoshi, T et al.	Int J Cardiol 2014	Not a randomized controlled trial
9	Statins for prevention of contrast-induced nephropathy in patients undergoing non- emergent percutaneous coronary intervention	Kandula, P et al.	Nephrology (Carlton) 2010	Not a randomized controlled trial
10	Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency	Yoshida, S et al.	J Cardiol 2009	Not a randomized controlled trial Treatment group defined as chronic pravastatin use
11	Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty	Zhao, J. L. et al.	Int J Cardiol 2008	Not a randomized controlled trial

Supporting Tables

 Table S1. The Cochrane Collaboration's tool for assessing risk of bias

Study	Domain	Support for judgment & review authors' judgment	Jadad Score			
Acikel et al.	Random Sequence Generation	Low risk of bias. Patients were randomized in 1:1 ratio to either CG or AG using a simple randomization method.				
	Allocation concealment	Low risk of bias. Allocation concealment was not maintained througout the study. First patient was randomly assigned to AG via a coin toss. Subsequent patients were then assigned to CG or AG in an alternating manner. However, the review authors judge that the outcome is not likely to be influenced by lack of concealment since all of the clinical outcome were objective findings.				
	Blinding of participants and personnel	Low risk of bias. The study was a open-label trial comparing atrovastatin and non-treatment group. However, the review authors judge that the outcome is not likely to be influenced since the treatmnet protocol was pre-specified and the primary and additional endpoints were laboratory results.	2			
	Blinding of outcome assessment	Unclear. Insufficient information to permit judgment. Independency of laboratory measurement not stated.				
	Incomplete outcome data	Low risk of bias. A total of 160 patients were completely followed to the end of the study. None of the patients were excluded from final analysis.				
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner.				
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.				
ARMYDA-CIN	Random Sequence Generation	Low risk of bias. Patients were assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers.				
	Allocation concealment	Low risk of bias. Central randomization. Randomization blocks were created and distributed to the 2 centers.				
	Blinding of participants and personnel	Low risk of bias. Double blinded placebo controlled clinical trial Physicians performing the procedure and follow-up assessment were not aware of the randomization assignment.				
	Blinding of outcome assessment	Low risk of bias. The primary and secondary ouputs include objective labroatory test.				
	Incomplete outcome data	Low risk of bias. A total of 241 patients were completely followed to the end of the study. None of the patients were excluded from final analysis				
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner				
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.				
Cao et al.	Random Sequence Generation	Low risk of bias. Patients were randomly allocated	2			
	Allocation concealment	Unclear. Insufficient information to permit judgment, it is not clear whether allocation	2			

		concealment was maintained throughout the study.	
	Blinding of participants and personnel	Low risk of bias. Open-label study. Although, both patients and investigators were aware of the	
		study group assignment, the review authors judge that the outcome is note likely to be	
		influenced by unblinding since the treatmnet protocol was pre-specified and the primary	
		endpoint was laboratory result.	
	Blinding of outcome assessment	Unclear. Insufficient information to permit judgment. Independency of laboratory measurement and detection method not stated.	
	Incomplete outcome data	Low risk of bias. A total of 180 patients were completely followed to the end of the study.	
		None of the patients were excluded from final analysis.	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner.	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
Hua et al.	Random Sequence Generation	Low risk of bias. Patients were randomly allocated.	
	Allocation concealment	Unclear. Insufficient information to permit judgment, it is not clear whether allocation concealment was maintained throughout the study.	
	Blinding of participants and personnel	Low risk of bias. Open-label study. Although, both patients and investigators were aware of the	
		study group assignment, the review authors judge that the outcome is note likely to be	
		influenced by unblinding since the treatmnet protocol was pre-specified and the primary	
		endpoint was laboratory result.	2
	Blinding of outcome assessment	Unclear. Insufficient information to permit judgment, it is not clear who performed serum creatinine measurement and the laboratory method.	2
	Incomplete outcome data	Low risk of bias. A total of 173 patients were completely followed to the end of the study. None of the patients were excluded from final analysis.	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
NAPLES II	Random Sequence Generation	Low risk of bias. Randomization was performed by a 1:1 ratio with computer-generated random numbers.	
	Allocation concealment	Unclear. Insufficient information to permit judgment, it is not clear whether allocation concealment was maintained throughout the study.	
	Blinding of participants and personnel	Low risk of bias. Open-label study. Although, both patients and investigators were aware of the study group assignment, the review authors judge that the outcome is note likely to be influenced by unblinding since the treatmnet protocol was pre-specified and the primary and additional endpoints were laboratory results.	3
	Blinding of outcome assessment	Unclear. Insufficient information to permit judgment. Independency of laboratory measurement and detection method not stated.	
	Incomplete outcome data	Low risk of bias. Despite of the 4% loss to follow-up rate, the authors provided daate of 17 patients lost at follow-up which were largely similar to those analyzed.	

	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner.	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
Ozhan et al.	Random Sequence Generation	Low risk of bias. The patients were randomized to a short-term highdose atorvastatin plus NAC or only NAC.	
	Allocation concealment	Unclear. Insufficient information to permit judgment, it is not clear whether allocation concealment was maintained throughout the study.	
	Blinding of participants and personnel	Low risk of bias. Open-label study. Although, both patients and investigators were aware of the study group assignment, the review authors judge that the outcome is note likely to be influenced by unblinding since the treatmnet protocol was pre-specified and the primary endpoint was laboratory result.	3
	Blinding of outcome assessment	Unclear. Insufficient information to permit judgment. Independency of laboratory measurement not stated.	
	Incomplete outcome data	Low risk of bias. A total of 130 patients were completely followed to the end of the study. None of the patients were excluded from final analysis.	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner.	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
PRATO-ACS	Random Sequence Generation	Low risk of bias. Randomization was performed by computerized using an electronic spreadsheet with blocks of 50 patients each.	
	Allocation concealment	Low risk of bias. Randomization was performed on admission by computerized assignment.	
	Blinding of participants and personnel	Low risk of bias. Although, both patients and investigators were aware of the study group assignment, the review authors judge that the outcome is note likely to be influenced by unblinding since the treatmnet protocol was pre-specified and the primary and additional endpoints were laboratory results.	
	Blinding of outcome assessment	Low risk of bias. All tests were done in the author's hospital laboratory with consistent methodology.	5
	Incomplete outcome data	Low risk of bias. Data are missing in both intervention groups, but reasons for these are both reported and balanced.	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner. The study protocol is available (<u>http://clinicaltrials.gov/show/NCT01185938</u>)	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
PROMISS	Random Sequence Generation	Low risk of bias. Patients were randomized 1:1 by computer generated permuted block of 6 patients.	
	Allocation concealment	Low risk of bias. Patients were randomized by computer generated codes provided by the research member of the center after enrollment.	5
	Blinding of participants and personnel	Low risk of bias. Eligible patients were randomly assigned to receive simvastatin or placebo.	

		Both patients and investigators were blinded to study group assignment	
	Blinding of outcome assessment	Low risk of bias. Serum creatinine levels were determined in a blinded fashion by laboratory	
		personnel. Analysis was performed using autoanalyzers located in independent department of	
		the center.	
	Incomplete outcome data	Low risk of bias. Data are missing in both intervention groups, but reasons for these are both	
		reported and balanced. (6/124 (4.8%) from treatment group and 5/123 (4.1%) due to	
		incomplete laboratory test results).	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of	
		interest in the review have been reported in the pre-specified manner.	
		The study protocol is available (<u>http://clinicaltrials.gov/show/NCT00259441</u>)	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
Toso et al.	Random Sequence Generation	Low risk of Bias. Randomization was performed by computerized assignment.	
	Allocation concealment	Unclear. Insufficient information to permit judgment, it is not clear whether allocation	
		concealment was maintained throughout the study, but the review authors judge that the	
		outcome is not likely to be influenced by lack of blinding since all of the clinical outcome were	
		objective findings.	
	Blinding of participants and personnel	Low risk of Bias. Although the study was a open-label placebo controlled trial, the review	
		authors judge that the outcome is note likely to be influenced by unblinding since the treatmnet	
		protocol was pre-specified and the primary and additional endpoints were laboratory results or	5
		objective outcome (death and need for dialysus/hemofiltration)	-
	Blinding of outcome assessment	Low risk of bias. Serum creatinine levels tests were performed in the same hospital laboratory	
	T 1, , 1,	with consistent methods.	
	Incomplete outcome data	Low risk of bias. All patients presented for creatinine determination and clinical follow-up at 1	
	C. L	month.	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of	
	Other sources of bias	interest in the review have been reported in the pre-specified manner.	
TRACK-D		Low risk of bias. The study appears to be free of other sources of bias.	
IKACK-D	Random Sequence Generation	Low risk of bias. Block randomization was performed using computerized assignment with a block size of 6.	
	Allocation concealment	Low risk of bias. Randomization was performed using computerized assignment by blinded	
	Anocation conceannent	envelopes.	
	Blinding of participants and personnel	Low risk of bias. Open-label study. Although, both patients and investigators were aware of the	
	binding of participants and persolliter	study group assignment, the review authors judge that the outcome is note likely to be	3
		influenced by unblinding since the treatment protocol was pre-specified and the primary	
		endpoint was laboratory result.	
	Blinding of outcome assessment	Low risk of bias. All events and biomarkers were collected and adjudicated by a blinded,	
	Dimening of outcome assessment		
		independent committee.	

	Incomplete outcome data	Low risk of bias. Data are missing in both intervention groups, but reasons for these are both reported and balanced. The study protocol is available (<u>http://clinicaltrials.gov/show/NCT00786136</u>)	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner.	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
Wei Li et al.	Random Sequence Generation	Low risk of bias. Eligible patients were randomly assigned in a 1: 1 ratio to receive atorvastatin or placebo	
	Allocation concealment	Unclear. Insufficient information to permit judgment, it is not clear whether allocation concealment was maintained throughout the study, but the review authors judge that the outcome is not likely to be influenced since all of the clinical outcome were objective findings.	
	Blinding of participants and personnel	Low risk of bias. The study is a double-blinded placebo-controlled trial.	
	Blinding of outcome assessment	Low risk of bias. The primary and secondary ouputs include objective labroatory test.	
	Incomplete outcome data	Low risk of bias. A total of 161 patients were completely followed to the end of the study. None of the patients were excluded from final analysis. Exlcusion of non-PCI patient was done after randomization (12/90 (13.3%) for treatment group and 7/90 (7.8%) for control group). However, the review authors judge that the outcome is not likely to be influenced since the baseline characteristics of both group remained similar between groups	4
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
Xinwei et al.	Random Sequence Generation	Low risk of bias. Patients were randomized 1:1 by a computer-generated permuted block of 8 patients	
	Allocation concealment	Low risk of bias. Randomized codes were provided by the research member of the center who was unaware of the data in the present study.	
	Blinding of participants and personnel	Low risk of bias. Although, both patients and investigators were aware of the study group assignment, the review authors judge that the outcome is note likely to be influenced by unblinding since the treatmnet protocol was pre-specified and the primary and additional endpoints were laboratory results.	3
	Blinding of outcome assessment	Unclear. Insufficient information to permit judgment. Independency of laboratory measurement and detection method not stated.	
	Incomplete outcome data	Low risk of bias. A total of 228 patients were completely followed to the end of the study. None of the patients were excluded from final analysis.	
	Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner.	
	Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.	
Zhao Xia et al.	Random Sequence Generation	Low risk of bias. Patients were randomly allocated	3

Allocation concealment	Unclear. Insufficient information to permit judgment, it is not clear whether allocation
	concealment was maintained throughout the study.
Blinding of participants and personnel	Low risk of Bias. Although the study was a open-label trial, the review authors judge that the outcome is note likely to be influenced by unblinding since the treatmnet protocol was pre-specified and the primary and additional endpoints were laboratory results.
Blinding of outcome assessment	Unclear. Insufficient information to permit judgment, it is not clear who performed serum creatinine measurement and the laboratory method.
Incomplete outcome data	Low risk of bias. A total of 100 patients were completely followed to the end of the study. None of the patients were excluded from final analysis.
Selective reporting	Low risk of bias. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified manner.
Other sources of bias	Low risk of bias. The study appears to be free of other sources of bias.

Figure S1. Risk of Bias Graph and Summary Figure




Figure S2. Risk of Bias Graph and Summary Figure




Figure S3. Overall Fixed Effects Model




Figure S4. Assessment of the Small Study Effect Bias




Figure S5. Influence of Individual Studies

	Study Omitted	Year	RR (95% CI)
1	PROMISS	2008	0.44 (0.34, 0.57)
2	Toso et al.	2009	0.42 (0.33, 0.53)
3	Xinwei et al.	2009	0.45 (0.35, 0.59)
4	Zhou Xia et al.	2009	0.45 (0.35, 0.58)
5	Acikel et al.	2010	0.44 (0.34, 0.58)
6	Ozhan et al.	2010	0.45 (0.35, 0.58)
7	Hua et al.	2010	0.45 (0.34, 0.58)
8	ARMYDA-CIN	2011	0.45 (0.34, 0.59)
9	Wei Li et al.	2012	0.47 (0.37, 0.59)
10	NAPLES II	2012	0.49 (0.39, 0.62)
11	CAO et al.	2012	0.46 (0.35, 0.59)
12	PRATO-ACS	2014	0.44 (0.33, 0.59)
13	TRACK-D	2014	0.41 (0.32, 0.54)
Tota	II (Random Effect Mod	del)	0.45 (0.35, 0.57)




Figure S6. Cumulative Meta-analysis

Study	Published Yea	r						RR (95% CI)
PROMISS	2008				•		-	0.75 (0.17, 3.28)
Toso et al.	2009				-	-		0.90 (0.49, 1.66)
Xinwei et al.	2009							0.63 (0.32, 1.25)
Zhou Xia et al.	2009				<u> </u>			0.59 (0.30, 1.14)
Acikel et al.	2010				_ <u>+</u>			0.60 (0.35, 1.04)
Ozhan et al.	2010							0.59 (0.37, 0.94)
Hua et al.	2010			+	-			0.55 (0.36, 0.83)
ARMYDA-CIN	2011				•			0.51 (0.35, 0.75)
Wei Li et al.	2012							0.47 (0.32, 0.69)
NAPLES II	2012		-					0.40 (0.28, 0.59)
CAO et al.	2012							0.40 (0.29, 0.55)
PRATO-ACS	2014							0.41 (0.32, 0.54)
TRACK-D	2014							0.45 (0.35, 0.57)
		.1	.2	.5		1 2	і 5	Т 10
			۔۔ urs High-d		•		ours Contro	

Figure S7. Random Effects Model of Change of Serum Creatinine

					Statin		Control	%
Study	Published Year		SMD (95% CI)	N	mean (SD), mg/dL	N	mean (SD), mg/dL	
PROMISS	2008		-0.08 (-0.33, 0.18)	118	.002 (0.16)	118	3 0.02 (0.23)	10.37
Toso et al.	2009		-0.07 (-0.30, 0.15)	152	0.07 (0.30)	152	2 0.09 (0.23)	10.70
Zhou Xia et al.	2009	•	-0.24 (-0.63, 0.15)	50	0.07 (0.24)	50	0.13 (0.26)	8.69
Acikel et al.	2010	-	-0.48 (-0.80, -0.17)	80	0.07 (0.15)	80	0.15 (0.18)	9.67
Ozhan et al.	2010		-0.39 (-0.74, -0.04)	60	-0.02 (0.13)	70	0.06 (0.25)	9.25
Hua et al.	2010	•	-0.29 (-0.59, 0.01)	76	0.27 (0.45)	97	0.41 (0.50)	9.82
ARMYDA-CIN	2011		-0.19 (-0.45, 0.06)	120	0.02 (0.35)	121	0.08 (0.27)	10.39
Wei Li et al.	2012		-0.92 (-1.24, -0.59)	78	0.13 (0.19)	83	0.34 (0.26)	9.54
CAO et al.	2012		-1.13 (-1.44, -0.81)	90	0.06 (0.19)	90	0.28 (0.20)	9.66
TRACK-D	2014	-	-0.03 (-0.10, 0.04)	1498	0.00 (0.29)	150	0 0.01 (0.33)	11.91
Overall Rando	m Effect Model	>	-0.37 (-0.59, -0.15)	2889		293	6	100.0
•	y P < 0.001; I² = 88.3% all Effect Z = 3.29 (P = 0.001)		Mean Change of Ser	um Cre	atinine (mg/dL)			
	I İ -1.44 mg/dL -0.3	7 0	ا 1.44 mg/dL					
	Favours High-dose Statin		Favours Control					

Figure S8. Subgroup According to Type of Contrast




Figure S9. Subgroup According to Age of Patients

				Events,	Events,	%
Study	Published Year		RR (95% CI)	Statin	Control	Weight
<u>Mean Age ≥ 60</u>						
PROMISS	2008		0.75 (0.17, 3.28)	3/118	4/118	2.66
Toso et al.	2009		0.94 (0.48, 1.83)	15/152	16/152	11.68
Xinwei et al.	2009		0.34 (0.14, 0.82)	6/113	18/115	7.00
Zhou Xia et al.	2009		0.14 (0.01, 2.70)	0/50	3/50	0.68
Hua et al.	2010		0.40 (0.15, 1.04)	5/76	16/97	6.06
ARMYDA-CIN	2011		0.38 (0.15, 0.93)	6/120	16/121	6.76
Wei Li et al.	2012		0.16 (0.04, 0.70)	2/78	13/83	2.73
NAPLES II	2012		0.25 (0.12, 0.51)	9/202	37/208	10.69
CAO et al.	2012		0.33 (0.14, 0.80)	6/90	18/90	7.15
PRATO-ACS	2014		0.45 (0.26, 0.77)	17/252	38/252	16.52
TRACK-D	2014		0.59 (0.39, 0.89)	34/1498	58/1500	25.02
Subtotal Effect (Z Heterogeneity	L = 5.76, Ρ < 0.001) (Ρ = 0.231 , Ι² = 22.3%)	\diamond	0.44 (0.34, 0.58)	103/2749	237/2786	96.95
<u> Mean Age < 60</u>						
Acikel et al.	2010 ←	•	0.33 (0.01, 8.06)	0/80	1/80	0.58
Ozhan et al.	2010		0.33 (0.07, 1.54)	2/60	7/70	2.47
Subtotal Effect (Z Heterogeneity	L = 1.56, Ρ = 0.119) (Ρ = 1.000 , Ι² = 0.0%)		0.33 (0.08, 1.33)	2/140	8/150	3.05
	Effect Model P = 0.364; l² = 8.2% l Effect Z = 6.44 (P < 0.001)	\diamond	0.45 (0.35, 0.57)	105/2889	245/2936	100.00
		.1 .2 .5 1 2 5	і 10			
			urs Control			

Figure S10. Subgroup According to Chronic Kidney Disease

				Events,	Events,	%
Study	Published Year		RR (95% CI)	Statin	Control	Weight
Studies with CK	D patients (eGFR < 60 ml/min)				
PROMISS	2008		0.75 (0.17, 3.28)	3/118	4/118	2.66
Toso et al.	2009		0.94 (0.48, 1.83)	15/152	16/152	11.68
NAPLES II	2012		0.25 (0.12, 0.51)	9/202	37/208	10.69
TRACK-D	2014		0.59 (0.39, 0.89)	34/1498	58/1500	25.02
•	Z = 2.10, P = 0.036) v (P = 0.055 , I² = 60.5%)	\diamond	0.55 (0.31, 0.96)	61/1970	115/1978	50.05
Without underly	ing CKD (eGFR ≥ 60 ml/min)					
Xinwei et al.	2009		0.34 (0.14, 0.82)	6/113	18/115	7.00
Zhou Xia et al.	2009		0.14 (0.01, 2.70)	0/50	3/50	0.68
Acikel et al.	2010 ←	•	0.33 (0.01, 8.06)	0/80	1/80	0.58
Ozhan et al.	2010		0.33 (0.07, 1.54)	2/60	7/70	2.47
Hua et al.	2010	•	0.40 (0.15, 1.04)	5/76	16/97	6.06
ARMYDA-CIN	2011		0.38 (0.15, 0.93)	6/120	16/121	6.76
Wei Li et al.	2012	• +	0.16 (0.04, 0.70)	2/78	13/83	2.73
CAO et al.	2012		0.33 (0.14, 0.80)	6/90	18/90	7.15
PRATO-ACS	2014		0.45 (0.26, 0.77)	17/252	38/252	16.52
Subtotal Effect (Z Heterogeneity	2 = 6.00, Ρ < 0.001) (Ρ = 0.973 , Ι² = 0.0%)	\diamond	0.37 (0.27, 0.51)	44/919	130/958	49.95
	Effect Model P = 0.364; I² = 8.2% I Effect Z = 6.44 (P < 0.001)	\Diamond	0.45 (0.35, 0.57)	105/2889	245/2936	100.00
			1			
	-	.1 .2 .5 1 2 5 h-dose Statin Favor	10 urs Control			

Figure S11. Subgroup According to Acute Coronary Syndrome

							Events,	Events,	%
Study	Published Year					RR (95% CI)	Statin	Control	Weight
Studies with Acu	ite coronary Syndrome								
Xinwei et al.	2009		-			0.34 (0.14, 0.82)	6/113	18/115	7.00
ARMYDA-CIN	2011		_			0.38 (0.15, 0.93)	6/120	16/121	6.76
Wei Li et al.	2012		•			0.16 (0.04, 0.70)	2/78	13/83	2.73
CAO et al.	2012		-			0.33 (0.14, 0.80)	6/90	18/90	7.15
PRATO-ACS	2014	- +	-			0.45 (0.26, 0.77)	17/252	38/252	16.52
Subtotal Effect (Z Heterogeneity (= 5.36, P < 0.001) (P = 0.776 , I² = 0.0%)	\diamond				0.37 (0.26, 0.53)	37/653	103/661	40.16
Without Acute Co	oronary Syndrome								
PROMISS	2008		•	-		0.75 (0.17, 3.28)	3/118	4/118	2.66
Toso et al.	2009	-	•			0.94 (0.48, 1.83)	15/152	16/152	11.68
Zhou Xia et al.	2009 ←	•		-		0.14 (0.01, 2.70)	0/50	3/50	0.68
Acikel et al.	2010 ←	+ 				0.33 (0.01, 8.06)	0/80	1/80	0.58
Ozhan et al.	2010		_			0.33 (0.07, 1.54)	2/60	7/70	2.47
Hua et al.	2010		_			0.40 (0.15, 1.04)	5/76	16/97	6.06
NAPLES II	2012					0.25 (0.12, 0.51)	9/202	37/208	10.69
TRACK-D	2014	<u>+</u> ◆	-			0.59 (0.39, 0.89)	34/1498	58/1500	25.02
Subtotal Effect (Z Heterogeneity (= 3.58, P < 0.001) (P = 0.236 , I² = 24.2%)	\diamond	>			0.50 (0.34, 0.73)	68/2236	142/2275	59.84
	ffect Model P = 0.364; I² = 8.2% Effect Z = 6.44 (P < 0.001)	\diamond				0.45 (0.35, 0.57)	105/2889	245/2936	100.00
				Ţ	T				
	_	.1 .2 .5 igh-dose Statin	12	5 Favou	10	_			

Figure S12. Subgroup According to N-acetylcystein

				Events,	Events,	%
Study	Published Year		RR (95% CI)	Statin	Control	Weight
With N-acetylcysteir	n as adjunctive therapy					
Toso et al.	2009		0.94 (0.48, 1.83)	15/152	16/152	11.68
Ozhan et al.	2010		0.33 (0.07, 1.54)	2/60	7/70	2.47
NAPLES II	2012		0.25 (0.12, 0.51)	9/202	37/208	10.69
PRATO-ACS	2014		0.45 (0.26, 0.77)	17/252	38/252	16.52
Subtotal Effect (Z = 2. Heterogeneity (P =		\diamond	0.46 (0.25, 0.83)	43/666	98/682	41.35
Without N-acetylcys	tein as adjunctive therapy	<u>,</u>				
PROMISS	2008		0.75 (0.17, 3.28)	3/118	4/118	2.66
Xinwei et al.	2009	• • ·	0.34 (0.14, 0.82)	6/113	18/115	7.00
Zhou Xia et al.	2009 <	+ <u> </u>	0.14 (0.01, 2.70)	0/50	3/50	0.68
Acikel et al.	2010 ←	•	- 0.33 (0.01, 8.06)	0/80	1/80	0.58
Hua et al.	2010		0.40 (0.15, 1.04)	5/76	16/97	6.06
ARMYDA-CIN	2011	•	0.38 (0.15, 0.93)	6/120	16/121	6.76
Wei Li et al.	2012 -		0.16 (0.04, 0.70)	2/78	13/83	2.73
CAO et al.	2012		0.33 (0.14, 0.80)	6/90	18/90	7.15
TRACK-D	2014		0.59 (0.39, 0.89)	34/1498	58/1500	25.02
Subtotal Effect (Z = 5. Heterogeneity (P =		\$	0.45 (0.34, 0.60)	62/2223	147/2254	58.65
Overall (I-squared = 8.	· •	\diamond	0.45 (0.35, 0.57)	105/2889	245/2936	100.00
Heterogeneity P = (0.364; l² = 8.2% ect Z = 6.44 (P < 0.001)					

Favours High-dose Statin Favours

Favours Control